The cause of elevated level of amyloid β‐peptide (Aβ42) in common late‐onset sporadic [Alzheimer’s
disease (AD)] has not been established. Here, we show that the membrane lipid …

KRAS is frequently mutated in nonsmall cell lung cancer (NSCLC), resulting in the activation
of the MAPK/ERK kinase (MEK)/ERK pathway. High‐throughput mutation profile has shown …

A PARP inhibitor is a rationally designed targeted therapy for cancers with impaired DNA
repair abilities. RAD51C is a paralog of RAD51 that has an important role in the DNA damage …

Notch-1 (Notch) is a cell surface receptor that regulates cell-fate decisions in the developing
nervous system, and it may also have roles in synaptic plasticity in the adult brain. Binding …

Background Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) has been
shown to exert a synergistic antitumor effect when combined with fluoropyrimidine. This …

HER2 overexpression is observed in 5–25% of gastric cancers. Lapatinib is a dual inhibitor
of the epidermal growth factor receptor and HER2 tyrosine kinase. We examined the …

Background Cetuximab has shown clinical benefit in patients with metastatic colorectal
cancer (mCRC) harboring wild-type RAS. Human epidermal growth factor receptor 2 (HER2) …

Src is a nonreceptor tyrosine kinase involved in the cross-talk and mediation of many signaling
pathways that promote cell proliferation, adhesion, invasion, migration, and tumorigenesis…

Accumulation of amyloid-β (Aβ) is widely accepted as the key instigator of Alzheimer’s
disease (AD). The proposed mechanism is that accumulation of Aβ results in inflammatory …

EGFR tyrosine kinase inhibitors have shown promising efficacy in the treatment of tumors with
EGFR mutations and amplifications. However, tyrosine kinase inhibitors have also proven …